CRDF - Company ID 0001213037
The table below shows Cardiff Oncology, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $41.00K | $120.00K | $121.00K | $109.00K | $165.00K | $163.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Cardiff Oncology, Inc. reported annual revenue of $593.00K for fiscal year 2025. That is down 13.2% from $683.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $381.07K (FY 2016) to $593.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.13M |
| $3.90M |
| $3.32M |
| $4.01M |
| $3.13M |
| $3.21M |
| Operating income | -$12.85M | -$11.97M | -$14.78M | -$14.38M | -$12.60M | -$12.54M |
| Income tax | - | - | - | - | - | - |
| Net income | -$12.35M | -$11.26M | -$13.94M | -$13.43M | -$11.86M | -$11.78M |
| EPS (diluted) | -$0.18 | -$0.17 | -$0.21 | -$0.20 | -$0.25 | -$0.26 |